title: Endogenous opiates modulate the postapnea ventilatory response in the obstructive sleep apnea syndrome.
abstract: Defense of ventilatory homeostasis against recurrent hypercapnia, hypoxia, and acidosis resulting from apnea in obstructive sleep apnea syndrome (OSAS) is dependent on compensatory mechanisms operative between episodes of airway obstruction. This investigation was designed to examine whether endogenous opiate activity modulates the compensatory ventilatory response to apnea in OSAS. Polysomnography and quantitative measurement of tidal volume was performed in 12 patients with moderate to severe OSAS during a morning nap study before and after intravenous administration of 10 mg of naloxone. Apnea index was not significantly altered. There was a small but significant shortening of apneas (postnaloxone apnea duration, 91.2% of prenaloxone; p = 0.002 by ANOVA). Tidal volume of the first postapnea breath and minute ventilation extrapolated from the first two postapnea breaths, but not frequency, increased significantly after naloxone (postnaloxone first breath volume, 112.7% of prenaloxone value [p = 0.03], with a similar increase for minute ventilation, 115.1% [p = 0.007]). The volume of the first postapnea breath was correlated with the duration of the previous apnea, both before (r = 0.59, p = 0.0001) and after naloxone. Despite this, analysis of covariance with apnea duration as the covariate confirmed a significant independent increase in postapnea breath volume after naloxone (p = 0.001). Naloxone also altered sleep architecture, increasing percent time awake during the study period (prenaloxone, 36.3 +/- 15.6%; postnaloxone, 56.7 +/- 22.4%; p = 0.0003) and decreasing total sleep time and percent time in Stage 1. Furthermore, naloxone increased continuity of awake periods (mean length of awake periods increased from 27.0 +/- 8.4 to 66.0 +/- 66.6 s after naloxone, p = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, New York University Medical Center, New York 10016.
authors.forename: H E
authors.initials: HE
authors.lastname: Greenberg
authors.forename: D M
authors.initials: DM
authors.lastname: Rapoport
authors.forename: S A
authors.initials: SA
authors.lastname: Rothenberg
authors.forename: L A
authors.initials: LA
authors.lastname: Kanengiser
authors.forename: R G
authors.initials: RG
authors.lastname: Norman
authors.forename: R M
authors.initials: RM
authors.lastname: Goldring
mesh_terms: D000704:Analysis of Variance; D004723:Endorphins / Q000502:physiology*; D006801:Humans; D009270:Naloxone / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D012891:Sleep Apnea Syndromes / Q000503:physiopathology*; D014851:Wakefulness / Q000187:drug effects
chemical_list: D004723:Endorphins; D009270:Naloxone